Development of dividable one-step dry-coated tablets (dividable-OSDRC) and their evaluation as a new platform for controlled drug release

The purpose of this study is to develop novel dividable coated tablets that retain their characteristics even after they are divided. We prepared dividable one-step dry-coated tablets (dividable-OSDRC) using our own manufacturing process with double structure punches. The release pattern of the divi...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutical research Vol. 21; no. 7; pp. 1177 - 1183
Main Authors Ozeki, Yuichi, Watanabe, Yukinao, Okamoto, Hirokazu, Danjo, Kazumi
Format Journal Article
LanguageEnglish
Published United States Springer Nature B.V 01.07.2004
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The purpose of this study is to develop novel dividable coated tablets that retain their characteristics even after they are divided. We prepared dividable one-step dry-coated tablets (dividable-OSDRC) using our own manufacturing process with double structure punches. The release pattern of the dividable-OSDRC with hydroxypropyl methylcellulose (HPMC) or methacrylic acid copolymer LD (Eudragit) as an outer layer was investigated before and after the division, and dissolution profiles were statistically compared using difference factor f1 and similarity factor f2. The dividable-OSDRC with HPMC for sustained-release (compression pressure, 150 MPa; crashing strength, 6.1 N; friability, 0.05%; CV of divided tablet weight, 7.8%) showed statistically equivalent release patterns between the one-half and the whole (f1, 13.9; f2, 55.5) and between the one-half and the two-halves (5.5, 72.5). The surface area of the tablets affected the sustained-release profiles. Furthermore, the tablets made with Eudragit LD for timed-release (150 MPa. 12.8 N, 0.18%, 9.6%) also showed approximated release patterns before and after the division. We proved that dividable-OSDRC maintain their release characteristics after they are divided. We conclude that the dividable-OSDRC could be used as a new platform for the controlled release of drugs.
AbstractList The purpose of this study is to develop novel dividable coated tablets that retain their characteristics even after they are divided. We prepared dividable one-step dry-coated tablets (dividable-OSDRC) using our own manufacturing process with double structure punches. The release pattern of the dividable-OSDRC with hydroxypropyl methylcellulose (HPMC) or methacrylic acid copolymer LD (Eudragit) as an outer layer was investigated before and after the division, and dissolution profiles were statistically compared using difference factor f1 and similarity factor f2. The dividable-OSDRC with HPMC for sustained-release (compression pressure, 150 MPa; crashing strength, 6.1 N; friability, 0.05%; CV of divided tablet weight, 7.8%) showed statistically equivalent release patterns between the one-half and the whole (f1, 13.9; f2, 55.5) and between the one-half and the two-halves (5.5, 72.5). The surface area of the tablets affected the sustained-release profiles. Furthermore, the tablets made with Eudragit LD for timed-release (150 MPa. 12.8 N, 0.18%, 9.6%) also showed approximated release patterns before and after the division. We proved that dividable-OSDRC maintain their release characteristics after they are divided. We conclude that the dividable-OSDRC could be used as a new platform for the controlled release of drugs.
PURPOSEThe purpose of this study is to develop novel dividable coated tablets that retain their characteristics even after they are divided. METHODSWe prepared dividable one-step dry-coated tablets (dividable-OSDRC) using our own manufacturing process with double structure punches. The release pattern of the dividable-OSDRC with hydroxypropyl methylcellulose (HPMC) or methacrylic acid copolymer LD (Eudragit) as an outer layer was investigated before and after the division, and dissolution profiles were statistically compared using difference factor f1 and similarity factor f2. RESULTSThe dividable-OSDRC with HPMC for sustained-release (compression pressure, 150 MPa; crashing strength, 6.1 N; friability, 0.05%; CV of divided tablet weight, 7.8%) showed statistically equivalent release patterns between the one-half and the whole (f1, 13.9; f2, 55.5) and between the one-half and the two-halves (5.5, 72.5). The surface area of the tablets affected the sustained-release profiles. Furthermore, the tablets made with Eudragit LD for timed-release (150 MPa. 12.8 N, 0.18%, 9.6%) also showed approximated release patterns before and after the division. CONCLUSIONSWe proved that dividable-OSDRC maintain their release characteristics after they are divided. We conclude that the dividable-OSDRC could be used as a new platform for the controlled release of drugs.
The purpose of this study is to develop novel dividable coated tablets that retain their characteristics even after they are divided. We prepared dividable one-step dry-coated tablets (dividable-OSDRC) using our own manufacturing process with double structure punches. The release pattern of the dividable-OSDRC with hydroxypropyl methylcellulose (HPMC) or methacrylic acid copolymer LD (Eudragit) as an outer layer was investigated before and after the division, and dissolution profiles were statistically compared using difference factor f1 and similarity factor f2. The dividable-OSDRC with HPMC for sustained-release (compression pressure, 150 MPa; crashing strength, 6.1 N; friability, 0.05%; CV of divided tablet weight, 7.8%) showed statistically equivalent release patterns between the one-half and the whole (f1, 13.9; f2, 55.5) and between the one-half and the two-halves (5.5, 72.5). The surface area of the tablets affected the sustained-release profiles. Furthermore, the tablets made with Eudragit LD for timed-release (150 MPa. 12.8 N, 0.18%, 9.6%) also showed approximated release patterns before and after the division. We proved that dividable-OSDRC maintain their release characteristics after they are divided. We conclude that the dividable-OSDRC could be used as a new platform for the controlled release of drugs.
Author Ozeki, Yuichi
Okamoto, Hirokazu
Danjo, Kazumi
Watanabe, Yukinao
Author_xml – sequence: 1
  givenname: Yuichi
  surname: Ozeki
  fullname: Ozeki, Yuichi
  email: yu_ozeki@skk-net.com
  organization: Pharmaceutical Research & Technology Laboratory, Sanwa Kagaku Kenkyusho Co. Ltd., Gifu-City, Japan. yu_ozeki@skk-net.com
– sequence: 2
  givenname: Yukinao
  surname: Watanabe
  fullname: Watanabe, Yukinao
– sequence: 3
  givenname: Hirokazu
  surname: Okamoto
  fullname: Okamoto, Hirokazu
– sequence: 4
  givenname: Kazumi
  surname: Danjo
  fullname: Danjo, Kazumi
BackLink https://www.ncbi.nlm.nih.gov/pubmed/15290857$$D View this record in MEDLINE/PubMed
BookMark eNpdkc1u1DAQgC1URLeFV0BWDwgOWWzHjuPe2m2hSEVF_EjcLMcZQyonDrazqI_AW9dLV1TCh_FhvvnRfEfoYAoTIHRCyZoSVr89P_10dfZxTXavrgnh67ZVol539glaUSHrShH-_QCtiGS8aiWnh-gopduCt1TxZ-iQCqZIK-QK_bmALfgwjzBlHBzuh-3Qm84DLjOrlGHGfbyrbDAZepx3mZzw639YdfPl4vPmDTZTyf6EIWLYGr-YPIQJm4QNnuA3nr3JLsQRl4BtmHIM3pd-fVx-4AgeTILn6KkzPsGL_X-Mvr27_Lq5qq5v3n_YnF1XtuYsV9RyBcZZ1QjqGiplrxwHxjohWycYbUAKx4iVIKEVVIBsa0agVs4SZ8rBjtGrh75zDL8WSFmPQ7LgvZkgLEk3jWwkV7SAJ_-Bt2GJU9lNM8YkKSpkgU4fIBtDShGcnuMwmninKdE7W_pc72zpR1v6ry3d2VL8cj9h6UboH0v3eup7rESUOQ
CitedBy_id crossref_primary_10_1248_yakushi_128_951
crossref_primary_10_1016_j_jconrel_2011_09_065
crossref_primary_10_1016_j_ijpharm_2006_12_015
crossref_primary_10_1248_yakushi_127_2057
crossref_primary_10_2174_1381612829666230423144232
crossref_primary_10_1016_j_heliyon_2024_e29064
crossref_primary_10_1016_j_ijpharm_2006_11_042
crossref_primary_10_1016_j_jsps_2011_08_003
crossref_primary_10_4161_biom_1_1_17717
crossref_primary_10_1007_s11095_007_9315_3
crossref_primary_10_1080_10837450701212479
crossref_primary_10_4236_ojs_2012_23032
ContentType Journal Article
Copyright Copyright Kluwer Academic Publishers Jul 2004
Copyright_xml – notice: Copyright Kluwer Academic Publishers Jul 2004
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7RV
7TK
7X7
7XB
88E
8AO
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
K9.
KB0
M0S
M1P
NAPCQ
PQEST
PQQKQ
PQUKI
PRINS
7X8
DOI 10.1023/B:PHAM.0000033004.88953.bc
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
ProQuest Nursing and Allied Health Journals
Neurosciences Abstracts
Health Medical collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
AUTh Library subscriptions: ProQuest Central
ProQuest One Community College
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
Nursing & Allied Health Premium
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Pharma Collection
Neurosciences Abstracts
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList ProQuest One Academic Eastern Edition
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: AUTh Library subscriptions: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1573-904X
EndPage 1183
ExternalDocumentID 679245101
10_1023_B_PHAM_0000033004_88953_bc
15290857
Genre Journal Article
GroupedDBID ---
-4W
-56
-5G
-BR
-EM
-Y2
-~C
.86
.VR
06C
06D
0R~
0VY
123
199
1N0
1SB
2.D
203
28-
29O
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
3SX
3V.
4.4
406
408
409
40D
40E
53G
5QI
5VS
67N
67Z
6NX
78A
7RV
7X7
88E
8AO
8FI
8FJ
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAEOY
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AAQLM
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYOK
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBXA
ABDZT
ABECU
ABFTV
ABHLI
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABKTR
ABLJU
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABSXP
ABTEG
ABTHY
ABTKH
ABTMW
ABULA
ABUWG
ABWNU
ABXPI
ACAOD
ACBXY
ACDTI
ACGFS
ACHSB
ACHXU
ACIPQ
ACIWK
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPRK
ACZOJ
ADBBV
ADHHG
ADHIR
ADIMF
ADINQ
ADJJI
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADYPR
ADZKW
AEBTG
AEFIE
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFDYV
AFEXP
AFGCZ
AFKRA
AFLOW
AFQWF
AFRAH
AFWTZ
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
B-.
BA0
BBWZM
BDATZ
BENPR
BGNMA
BKEYQ
BPHCQ
BVXVI
CAG
CCPQU
CGR
COF
CS3
CSCUP
CUY
CVF
DDRTE
DL5
DNIVK
DPUIP
DU5
EBD
EBLON
EBS
ECM
EIF
EIOEI
EJD
EMOBN
EN4
EPAXT
ESBYG
EX3
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
GQ8
GXS
H13
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IAO
IHE
IJ-
IKXTQ
IMOTQ
INH
ITM
IWAJR
IXC
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
KDC
KOV
KOW
KPH
L7B
LAK
LLZTM
LSO
M1P
M4Y
MA-
MK0
N2Q
N9A
NAPCQ
NB0
NDZJH
NPM
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
OVD
P19
P2P
PF0
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
QOK
QOR
QOS
R4E
R89
R9I
RHV
RIG
RNI
RNS
ROL
RPX
RRX
RSV
RZC
RZE
RZK
S16
S1Z
S26
S27
S28
S3A
S3B
SAP
SBL
SBY
SCLPG
SDH
SHX
SISQX
SJYHP
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZN
T13
T16
TEORI
TSG
TSK
TSV
TUC
U2A
U9L
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WH7
WJK
WK6
WK8
WOW
YCJ
YLTOR
Z45
Z5O
Z7S
Z7U
Z7V
Z7W
Z7X
Z81
Z82
Z83
Z84
Z87
Z88
Z8N
Z8O
Z8P
Z8Q
Z8R
Z8V
Z8W
Z91
Z92
ZGI
ZMTXR
ZOVNA
~KM
AAYXX
ADOAH
CITATION
7TK
7XB
8FK
K9.
PQEST
PQUKI
PRINS
7X8
ID FETCH-LOGICAL-c342t-1c49eafc9651f6177d9f4e22b578f5216e75f20c7e7e8515e78320e39fc0fa003
IEDL.DBID BENPR
ISSN 0724-8741
IngestDate Fri Oct 25 21:32:43 EDT 2024
Thu Oct 10 16:09:36 EDT 2024
Thu Sep 12 18:55:30 EDT 2024
Wed Oct 16 00:51:23 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 7
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c342t-1c49eafc9651f6177d9f4e22b578f5216e75f20c7e7e8515e78320e39fc0fa003
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 15290857
PQID 222700237
PQPubID 37334
PageCount 7
ParticipantIDs proquest_miscellaneous_66767491
proquest_journals_222700237
crossref_primary_10_1023_B_PHAM_0000033004_88953_bc
pubmed_primary_15290857
PublicationCentury 2000
PublicationDate 2004-Jul
2004-07-00
20040701
PublicationDateYYYYMMDD 2004-07-01
PublicationDate_xml – month: 07
  year: 2004
  text: 2004-Jul
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: New York
PublicationTitle Pharmaceutical research
PublicationTitleAlternate Pharm Res
PublicationYear 2004
Publisher Springer Nature B.V
Publisher_xml – name: Springer Nature B.V
SSID ssj0008194
Score 1.8401837
Snippet The purpose of this study is to develop novel dividable coated tablets that retain their characteristics even after they are divided. We prepared dividable...
The purpose of this study is to develop novel dividable coated tablets that retain their characteristics even after they are divided. We prepared dividable...
PURPOSEThe purpose of this study is to develop novel dividable coated tablets that retain their characteristics even after they are divided. METHODSWe prepared...
SourceID proquest
crossref
pubmed
SourceType Aggregation Database
Index Database
StartPage 1177
SubjectTerms Acetaminophen - chemistry
Chemical Phenomena
Chemistry, Pharmaceutical
Chemistry, Physical
Compressive Strength
Delayed-Action Preparations - chemistry
Drug Compounding
Drug dosages
Excipients - chemistry
Hypromellose Derivatives
Kinetics
Manufacturing
Methylcellulose - analogs & derivatives
Methylcellulose - chemistry
Solubility
Tablets, Enteric-Coated - chemistry
Time Factors
Title Development of dividable one-step dry-coated tablets (dividable-OSDRC) and their evaluation as a new platform for controlled drug release
URI https://www.ncbi.nlm.nih.gov/pubmed/15290857
https://www.proquest.com/docview/222700237
https://search.proquest.com/docview/66767491
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Nb9MwFLdYd-GCYHyVwfYOaAJpZo0_6oULWj-mCmlbVDqpN8txbIQ0JaNJD_0T-K95TtKUHcYlF0e25Pdpv9_7mZCPits4i6KUSuM8Fdw7em4soyLjRlo-zM7rq-yr6-HsVnxfymWLzSlbWOXWJ9aOOitsuCM_Cz2bIcCob_e_aXg0KhRX2xc09sg-w4MC65H90fQ6mXeuGMNdzR-lmECzF9GWdZTxs9HXZHZx1dIXBtopVJlY8i-pfRihHkk76_Bz-Zw8a_NGuGgE_YI8cfkBOUka4unNKSx2fVTlKZxAsqOk3rwkf_7BBkHhYRKasELTFNzkjgakF0xWGzouMPPMYBFGqhI-db_Rmx-T-fgzmDwLK_1awbRjCQdTggF0lpDcmSrkwIAfGDcY-Ducb7Ja_4Q5xjeMmK_I7eV0MZ7R9hEGarlgFY2siJ3xNh7KyGO6o7LYC8dYiqbuMfYPnZKeDaxyymH2Jp1CHzFwPPZ24A3u7WvSy4vcvSXArFVMOm-4zYRzKrWoFjKN2MCHYmnUJ3y78fq-4drQdY2ccT3SQVx6Jy5di0untk8OtzLSrf2VutOWPjnuRtFwQjXE5K5YlzqAe5WIcdU3jWB3a0oWB-L_d_-d-ZA8bVA8Abr7nvSq1dp9wASlSo_Inlqqo1YZ_wIUqeOM
link.rule.ids 315,783,787,12070,21402,27938,27939,31733,31734,33758,33759,43324,43819,74081,74638
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NT9swFLcYHLbLtLEPCtt4hwltEh6NP2rCZYIW1G0UKlak3izHsScklLAmPfRP2H-NX5KmcGCXXBzZkt-n_X7vZ0I-K27jNIoSKo3zVHDv6KGxjIqUG2l5Lz2srrJHF73htfg5ldMGm1M0sMqlT6wcdZpbvCM_wJ5NDDDq-91fio9GYXG1eUHjGdlAGi6kzlfT9ryFwa5ij1JMBKMX0ZJzlPGDk6Px8HjUkBci6VRQmFjyb4l9HJ-eSDqr4HP2irxsskY4rsX8mqy5bJPsjWva6cU-TFZdVMU-7MF4RUi9eEP-PUAGQe5hgC1Y2DIFl5mjiPOCwWxB-3nIO1OY4EhZwJf2N3r5e3DV_womS3GlmxmcthzhYAowEFwljG9NiRkwhA_0awT8bZhvMJv_gasQ3UK8fEuuz04n_SFtnmCglgtW0siK2Blv456MfEh2VBp74RhLgqH7EPl7TknPulY55ULuJp0KHqLreOxt15uwt-_IepZnbosAs1Yx6bzhNhXOqcQGpZBJxLoeS6VRh_Dlxuu7mmlDVxVyxvWJRnHplbh0JS6d2A7ZWcpIN9ZX6FZXOmS3HQ1mg7UQk7l8XmiE9ioRh1Xf14JdrSlZjLT_2_-deZc8H05G5_r8x8WvHfKixvMgiPcDWS9nc_cxpCpl8qlSyHu1MeQw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIgL4s22QOeAKpBqduPHuuGC2k1Xy6NtVLbS3izHsRFSlbSb7GF_Av-acZLNwgEuuTiyJc945kv8zTeEvFXcxnkUZVQa56ng3tEjYxkVOTfS8nF-1PzKPjsfz67El4VcdJJCVUer3MTEJlDnpQ3_yIehZjMkGDX0HSsiTaafbm5paCAVLlq7bhp3yT0lMM-ha6tF_-0VEl-jJKWYwAAgoo3-KOPDk4_p7PisEzIMAlToPLHkHzL7d676BwBtEtH0EXnYIUg4bk3-mNxxxRNykLYS1OtDmG8rqqpDOIB0K069fkp-_cESgtJDEsqxQvkUXBSOBs4XJMs1nZSIQXOYh5G6gnf9a_Tie3I5eQ-myMNKP5dw2uuFg6nAAIZNSK9NHdAw4AMmLRv-GudLlqsfcImZDnPnM3I1PZ1PZrRrx0AtF6ymkRWxM97GYxl5BD4qj71wjGV46D2igLFT0rORVU45xHHSKYwWI8djb0fe4N4-JztFWbiXBJi1iknnDbe5cE5lFh1EZhEb-XBtGg0I32y8vmlVN3RzW864PtHBXHprLt2YS2d2QPY2NtLdSax07zcDst-P4hEK9yKmcOWq0oHmq0SMq75oDbtdU7I4tADY_e_M--Q--qL-9vn86x550FJ7Ap_3Fdmplyv3GlFLnb1p_PE3f8noZQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+of+Dividable+One-Step+Dry-Coated+Tablets+%28Dividable-OSDRC%29+and+Their+Evaluation+as+a+New+Platform+for+Controlled+Drug+Release&rft.jtitle=Pharmaceutical+research&rft.au=Ozeki%2C+Yuichi&rft.au=Watanabe%2C+Yukinao&rft.au=Okamoto%2C+Hirokazu&rft.au=Danjo%2C+Kazumi&rft.date=2004-07-01&rft.issn=0724-8741&rft.volume=21&rft.issue=7&rft.spage=1177&rft.epage=1183&rft_id=info:doi/10.1023%2FB%3APHAM.0000033004.88953.bc&rft.externalDBID=n%2Fa&rft.externalDocID=10_1023_B_PHAM_0000033004_88953_bc
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0724-8741&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0724-8741&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0724-8741&client=summon